.jpg)
.png)
All
At the NLA’s annual Honors and Awards ceremony, Chapter presidents have the opportunity to present Chapter President’s Service Awards. These awards are presented by each Chapter President to one or two members from their chapter who has provided exceptional service to the chapter over... more
Since loss-of-function mutations in proprotein convertase subtilisin-kexin type 9 (PCSK9) were found to be associated with reduction in low-density lipoprotein cholesterol levels (LDL-C) and coronary events1, there has been great anticipation of the development of effective therapeutic agents to... more
View the January 2019 SWLA E-Newsletter by clicking here.
The USAGE Campaign, which launched in 2012 as a joint initiative by the NLA, Kowa Pharmaceuticals America and Eli Lilly & Co., recently was honored with finalist designation for two major industry awards, the PRSA National Silver Anvil and the PRSA Big Apple Awards.
Click Here to Listen to the Podcast PROGRAM OVERVIEW: Evolving Standards in Familial Hypercholesterolemia: Innovations in Diagnosis and Therapeutic Strategies ACTIVITY TYPE Enduring Internet NLA ID: 2026014 ACTIVITY DATES Release Date: January 29, 2026 Expiration Date:... more
Amgen recently announced that the FOURIER trial met its primary and secondary endpoints in evaluating whether evolocumab reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) without new safety issues. Amgen also announced that... more
Introduction Patients diagnosed with serious mental illness prescribed antipsychotic medications present unique challenges to healthcare providers. The use of second- generation, or atypical, antipsychotics is associated with significant adverse metabolic effects. These include weight gain,... more
The metabolic syndrome is a clustering of interrelated risk factors for cardiovascular (CV) disease and type 2 diabetes. Although various definitions for the metabolic syndrome exist, several national and international health organizations — including the American Heart Association (AHA); the... more
Introduction Atherosclerotic Cardiovascular disease (ASCVD) is the leading cause of death worldwide, and uncontrolled lipids are a major modifiable risk factor for ASCVD.1 Statin therapy remains the cornerstone for ASCVD risk-reduction, yet optimal lipid control remains suboptimal.2 Current... more
The 2015 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw yet another significant increase — from 3.904 (2014) to 4.906 (2015). The Journal is now ranked 23rd out of 253 journals in its category (pharmacology and... more